Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Respiratory Drugs >  Asthma drugs >  Montelukast

Montelukast

Basic information Safety Supplier Related

Montelukast Basic information

Product Name:
Montelukast
Synonyms:
  • (r-(e))-1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
  • 2-[1-[[(1r)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid
  • Montelukas
  • Montelukast
  • Montelukast Acid
  • Montelukast(Form A)
  • (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid
  • Cyclopropaneaceticacid,1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]propyl]thio]Methyl]-
CAS:
158966-92-8
MF:
C35H36ClNO3S
MW:
586.18
EINECS:
256-723-9
Mol File:
158966-92-8.mol
More
Less

Montelukast Chemical Properties

Melting point:
145-148 °C(Solv: toluene (108-88-3); methanol (67-56-1))
Boiling point:
750.5±60.0 °C(Predicted)
Density 
1.272±0.06 g/cm3(Predicted)
pka
4.76±0.10(Predicted)
CAS DataBase Reference
158966-92-8(CAS DataBase Reference)
EPA Substance Registry System
Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (158966-92-8)
More
Less

Safety Information

Hazardous Substances Data
158966-92-8(Hazardous Substances Data)
More
Less

Montelukast Usage And Synthesis

Uses

cardiostimulant,

brand name

Singulair (Merck).

Mechanism of action

Montelukast was developed from other weakly antagonistic quinoline derivatives. A number of changes can be made to the structure without the loss of activity. These include changing the double bond between the two aromatic rings to an ether linkage, reducing the quinoline ring, changing the chlorine to a fluorine, and/or exchanging the sulfur for an amide group.

Pharmacokinetics

Montelukast is a high-affinity, selective antagonist of the cysLT1 receptor. It is rapidly absorbed orally, with a bioavailability of 64%. Montelukast is 99% bound to plasma proteins and is extensively metabolized in the liver by CYP3A4 and CYP2C9 to oxidated products. CYP3A4 oxidizes the sulfur and the C-21 benzylic carbon, whereas CYP2C9 is selectively responsible for the methyl hydroxylation.

Side effects

Montelukast did not demonstrate any significant adverse effects greater than placebo in clinical trials; however, because it is metabolized by the cytochrome P450 (CYP450) enzymes, its plasma levels should be monitored when coadministered with CYP450-inducing drugs, such as phenobarbital, rifampin, and phenytoin.

Montelukast Preparation Products And Raw materials

Raw materials

MontelukastSupplier

Wuxi Helen Biotechnology Co., Ltd., Gold
Tel
0510-85629785-
Email
sales@reading-chemicals.com
LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
XiaoGan ShenYuan ChemPharm co,ltd
Tel
0712-2580635- ;0712-2580635
Email
1791901229@qq.com;1791901229@qq.com;
Hangzhou Yuhao Chemical Technology Co., Ltd
Tel
0571-82693216
Email
info@yuhaochemical.com
Artis Chemistry (Shanghai) Co. Ltd.
Tel
86-21-60936353; 86-13918153394
Email
synthesis@artis-chem.com